EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

New horizons at the interface of artificial intelligence and translational cancer research

Josephine Yates, Eliezer M Van Allen

Cancer Cell · 2025-04 · 43 (4) · 708-727

DOI: 10.1016/j.ccell.2025.03.018 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancer Cell, 2025-04. Verfasst von Josephine Yates und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Institute for Machine Learning, Department of Computer Science, ETH Zü…. Hauptthemen laut MEDLINE: Artificial Intelligence, Neoplasms, Translational Research, Biomedical. Die Arbeit wurde bisher 57-mal zitiert (Crossref) und nennt 204 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, National Institutes of Health, Swiss National Science Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Artificial intelligence (AI) is increasingly being utilized in cancer research as a computational strategy for analyzing multiomics datasets. Advances in single-cell and spatial profiling technologies have contributed significantly to our understanding of tumor biology, and AI methodologies are now being applied to accelerate translational efforts, including target discovery, biomarker identification, patient stratification, and therapeutic response prediction. Despite these advancements, the integration of AI into clinical workflows remains limited, presenting both challenges and opportunities. This review discusses AI applications in multiomics analysis and translational oncology, emphasizing their role in advancing biological discoveries and informing clinical decision-making. Key areas of focus include cellular heterogeneity, tumor microenvironment interactions, and AI-aided diagnostics. Challenges such as reproducibility, interpretability of AI models, and clinical integration are explored, with attention to strategies for addressing these hurdles. Together, these developments underscore the potential of AI and multiomics to enhance precision oncology and contribute to advancements in cancer care.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Artificial IntelligenceNeoplasmsTranslational Research, BiomedicalHumansPrecision MedicineTumor MicroenvironmentBiomarkers, Tumor

Stichwörter der Autor:innen

AI-aided diagnosticsartificial intelligencecancermachine learningmultiomicstranslational oncology

Substanzen

Biomarkers, Tumor

Autor:innen und Institutionen

  • Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Institute for Machine Learning, Department of Computer Science, ETH Zürich, Zurich, Switzerland; ETH AI Center, ETH Zurich, Zurich, Switzerl…
  • Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Cancer Program, Broad Institute of MIT and Harvard, Cambridge, MA, USA; Division of Medical Sciences, Harvard University, Boston, MA, USA; P…

Förderung

  • NCI NIH HHS
  • National Institutes of Health
  • Swiss National Science Foundation
  • Ambrose Monell Foundation

Zitieren

APA

Yates, J., & Van Allen, E. M. (2025). New horizons at the interface of artificial intelligence and translational cancer research. Cancer Cell, 43(4), 708-727. https://doi.org/10.1016/j.ccell.2025.03.018

Vancouver

Yates J, Van Allen EM. New horizons at the interface of artificial intelligence and translational cancer research. Cancer Cell. 2025;43(4):708-727. doi:10.1016/j.ccell.2025.03.018

BibTeX
@article{Yates2025,
  author = {Yates, Josephine and Van Allen, Eliezer M},
  title = {New horizons at the interface of artificial intelligence and translational cancer research},
  journal = {Cancer Cell},
  year = {2025},
  volume = {43},
  number = {4},
  pages = {708--727},
  doi = {10.1016/j.ccell.2025.03.018}
}
Kostenlos starten →